Wed, Aug 27, 2014, 9:45 AM EDT - U.S. Markets close in 6 hrs 15 mins

Recent

% | $
Quotes you view appear here for quick access.

PDL BioPharma, Inc. Message Board

zero.risk13 100 posts  |  Last Activity: Aug 21, 2014 10:04 AM Member since: Oct 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    GTHP Will Soon Be Higher Priced

    by zero.risk13 Jul 15, 2014 10:17 AM
    zero.risk13 zero.risk13 Jul 15, 2014 11:49 AM Flag

    Almost there.

  • Resubmission of PMA next week = potential 10 bagger.
    International sales are accelerating.
    GTHP is the stock to be in now.

  • Approved beats 'maybe' approved in five years.
    70M shares beats 250M shares.
    .485 beats .574.
    $35M market cap beats $150M market cap.

    Less risk more value.

  • Reply to

    New to OTC

    by lancewerner17 Jul 12, 2014 12:32 AM
    zero.risk13 zero.risk13 Jul 12, 2014 3:29 PM Flag

    Overdiluted stocks are not long term investments.
    AMBS has some 800,000,000 shares outstanding and ONCS has around 300,000,000.
    They are nowhere near approval, so those numbers will increase dramatically.
    You might be able to catch a bounce on one of those stocks for a short term gain, but long term you will get destroyed.

    If you want a potential 10 bagger, GTHP is the stock.
    They have 70M shares outstanding and an approved product on the launch pad for a huge market.
    The cervical cancer scanners are sold for $20K and the disposable used in each scan for about $20.
    The disposable have an 80% to 90% profit margin. (It's like the razor blade business).
    60 million pap smear tests are taken annually in the US.
    That represents a potential $1 billion in profits on the disposables alone in the US.
    The international markets are even larger.

  • zero.risk13 zero.risk13 Jul 11, 2014 8:45 AM Flag

    Seriously? NAVB and EAPH.
    NAVB has overpromised and underdelivered for years. Their debt exceeds their cash and they are burning over $30M annually.
    EAPH is a Canadian penny biotech. Never buy Canadian biotechs.

    Go with a quality undervalued biotech like GTHP.
    Think long term, not just trying to catch a temporary bounce.
    Playing PDUFA dates is foolish gambling.

  • Reply to

    Setto

    by lopopswz Jul 11, 2014 7:26 AM
    zero.risk13 zero.risk13 Jul 11, 2014 8:27 AM Flag

    Opposing views are good. Why do you want to silence those who differ with your opinion?
    Your post is reeking with sarcasm and chest pounding.
    Do you seriously expect him to respond?

    I always find that the negative posts are more insightful than the self serving pump posts.
    If there is a stock that I am considering buying, I like to read the bearish posts.
    They contain information about management, or competing products or analysis of prior trials
    that is not readily available in company filings.

    Have you ever noticed when some horrid stock craters from $50 to 50 cents, followed by a
    dead dog bounce to $2, there will be pumpers reveling in a 40% or 60% gain instead of
    taking their profit, counting their blessings for catching a fleeting bounce and moving on
    to a quality stock.

    You asked for a stock to buy, here is one: GTHP.
    They have a biophotonic cervical cancer scan that is more accurate than pap smear tests and it produces instant test results.
    Over 60 million pap smear tests are taken annually in the US, so the market opportunity is huge.
    They will be resubmitting the PMA for US approval this month.
    Yesterday they received marketing approval in Mexico.
    The scan is also approved in the EU, Canada, Singapore.....
    International sales are projected to potentially reach $3M this year.
    The new CEO was formerly with Abbott and GE Diagnostics and has vast marketing experience.

    Sales are ramping up and the market cap is only $35M.
    Compare that to a stock with a market cap of $150M with nothing approved.
    Approval is a minimum of five years away, if ever, with only massive dilution to look forward to in the interim.
    Which is the better buy?

  • zero.risk13 by zero.risk13 Jul 10, 2014 5:52 PM Flag

    Chinese stocks always implode.

    GTHP has a biophotonic scan for cervical cancer.
    It will be huge!
    Over 60 million pap smear tests are taken annually in the US alone.
    GTHP' scan is more accurate and produces instant test results.
    They are already approved in the EU, Canada, Mexico, Singapore.....

  • Approved in EU, Canada, Mexico, Singapore
    Resubmission this month for FDA approval.

    Over 60 million pap smear tests are taken annually in the US alone.
    GTHP's biophotonic scan is more accurate and produces instant test results.

    Huge market. Small market cap. = potential 10 bagger this year.

  • Reply to

    O/T Dendreon has many parallels to GALE

    by jrdelane Jul 10, 2014 11:31 AM
    zero.risk13 zero.risk13 Jul 10, 2014 12:04 PM Flag

    DNDN is a disaster.
    Take the $2.30 and roll it over into GTHP.
    Read todays news: their HPV scan was just approved in Mexico (that's in addition to the EU, Canada, Singapore).
    Later this month they are resubmitting for FDA approval.

    GTHP will be a monster stock.
    Over 60 million pap smear tests are taken annually in the US alone.
    GTHP's biophotonic scan is more accurate and produces instant test results.
    Market cap is only $35M.
    Get in on the ground floor!!!!!!!!!!!!!!!!!

  • "Guided Therapeutics, Inc. (GTHP) (GTHP) today announced that LuViva® Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS).

    “Approval to sell LuViva in Mexico is a significant milestone for the company and opens up the second largest market for medical products in Latin America,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics. “We will be working with Dantien5 Medical, our distributor in Mexico, to promote LuViva for the detection of cervical cancer, a tremendous unmet need in this part of the world.”

    Cervical cancer is the leading cause of cancer in women of reproductive age in Mexico, and remains the second leading cause of cancer deaths in women."

  • HPV testing is a huge market.
    Over 60M pap smear test are taken annually in the US.
    GTHP's biophotonic scan is more accurate and produces instant test results.

    Orders from distributors are flowing in.
    Sales will accelerate in the next few quarters.
    GTHP has 10 bagger potential written all over it.

  • 1/6 the market cap for an APPROVED product for a huge market.
    GTHP's biophotonic scan for cervical cancer is approved in Canada, EU, Singapore .....
    FDA news is expected this week.
    Over 60 million pap smear tests are taken annually in the US.
    GTHP's scan is more accurate and produces instant test results.

    APPROVED for a huge market beats nothing on the horizon .....
    Market cap of only $35M.

  • zero.risk13 zero.risk13 Jun 24, 2014 2:44 PM Flag

    End of June 2014 ...... NOTHING, still NOTHING!

  • Electroporated belly up mice everywhere.

  • zero.risk13 zero.risk13 Jun 24, 2014 2:40 PM Flag

    Agreed ...... easy money on the short side ...... s it has ben for 34 years ...... $200 to $9.

  • Reply to

    A Point to Consider.....

    by penny.dung May 26, 2014 12:34 PM
    zero.risk13 zero.risk13 Jun 24, 2014 2:38 PM Flag

    Consider that.

  • Reply to

    What if Phase II fails?

    by golf.paul123 Jun 24, 2014 10:56 AM
    zero.risk13 zero.risk13 Jun 24, 2014 2:35 PM Flag

    It's not "what if" ..... the question should be WHEN it FAILS.
    The 34 year streak of FAILURE will continue.
    Never put your money on a lame nag.

  • The cervical cancer scan market is huge.
    Over 60M pap smear tests are taken annually.
    GTHP's biophotnonic scan is more accurate and produces instant results.
    It's already approved in Canada, EU, Singapore .....
    FDA news expected this week will send the stock rocketing.

  • zero.risk13 by zero.risk13 Jun 24, 2014 1:17 PM Flag

    and become wealthy beyond your wildest dreams.

    GTHP's biophotonic cervical cancer scan is approved in the EU, Canada and Singapore.
    Pending FDA approval will send the stock into the stratosphere.
    Over 60M pap smear test are taken annually in the US.
    GTHP's scan is more accurate and produces instant test results.
    The disposable used in each scan produces an 80% profit.
    Potential: 60M X $10 profit = $600M earnings
    Plus: profit on the sale of the scanners.
    Plus: international sales.

    Now is the time to load up ...... market cap is only $35M.

  • FDA news expected this week.
    Biophotonics to detect cancers is first in class technology.
    It's more accurate than pap smears and produces instant test results.
    Over 60M pap smear tests are taken annually in the US.
    GTHP will be HUGE!!!!!!!!!!!!

PDLI
9.84-0.06(-0.57%)9:45 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.